307 related articles for article (PubMed ID: 20190765)
1. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.
Li J; Rix U; Fang B; Bai Y; Edwards A; Colinge J; Bennett KL; Gao J; Song L; Eschrich S; Superti-Furga G; Koomen J; Haura EB
Nat Chem Biol; 2010 Apr; 6(4):291-9. PubMed ID: 20190765
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer.
Gordian E; Li J; Pevzner Y; Mediavilla-Varela M; Luddy K; Ohaegbulam K; Daniel KG; Haura EB; Muñoz-Antonia T
PLoS One; 2014; 9(12):e114131. PubMed ID: 25501935
[TBL] [Abstract][Full Text] [Related]
6. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
9. Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Klammer M; Kaminski M; Zedler A; Oppermann F; Blencke S; Marx S; Müller S; Tebbe A; Godl K; Schaab C
Mol Cell Proteomics; 2012 Sep; 11(9):651-68. PubMed ID: 22617229
[TBL] [Abstract][Full Text] [Related]
10. A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
Vojvodic M; Hansford LM; Morozova O; Blakely KM; Taylor P; Fathers KE; Moffat J; Marra M; Smith KM; Moran MF; Kaplan DR
Curr Drug Discov Technol; 2013 Dec; 10(4):283-304. PubMed ID: 23701117
[TBL] [Abstract][Full Text] [Related]
11. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
12. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
[TBL] [Abstract][Full Text] [Related]
13. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
14. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
18. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways.
Yan GR; Xiao CL; He GW; Yin XF; Chen NP; Cao Y; He QY
Proteomics; 2010 Mar; 10(5):976-86. PubMed ID: 20049867
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
20. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.
Ke J; Chelvarajan RL; Sindhava V; Robertson DA; Lekakis L; Jennings CD; Bondada S
Mol Cancer; 2009 Dec; 8():132. PubMed ID: 20043832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
